Bruce L. Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center of the University of Pennsylvania (Member), Abramson Cancer Center of the University of Pennsylvania (Member)
Deputy Director - Technology Innovation and Assessment, Center for Cellular Immunotherapies, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine
Founding Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine and Abramson Cancer Center
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations
Contact information
Center for Cellular Immunotherapies
Smilow 8-114
3400 Civic Center Boulevard
Philadelphia, PA 19104
Smilow 8-114
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-746-1481
Education:
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Post-Graduate Training
Post-doctoral Fellow, Henry M. Jackson Foundation, Naval Medical Research Institute, National Naval Medical Center, Bethesda, MD, 1992-1996.
Permanent linkPost-doctoral Fellow, Henry M. Jackson Foundation, Naval Medical Research Institute, National Naval Medical Center, Bethesda, MD, 1992-1996.
Description of Research Expertise
Immunology, Cell and Gene TherapyDescription of Other Expertise
Good Manufacturing PracticesDescription of Itmat Expertise
Dr. Levine's interests include cell, gene, and biologic therapy clinical trial development, manufacturing, and testing and lymphocyte growth, activation and senescence.Selected Publications
Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Barz Leahy A, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT.: Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19. Clin Cancer Res Jun 2022.Gill SI, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL.: Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Adv Mar 2022.
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH.: Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602(7897): 503-509, February 2022.
Odeh-Couvertier VY, Dwarshuis NJ, Colonna MB, Levine BL, Edison AS, Kotanchek T, Roy K, Torres-Garcia W.: Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. Bioeng Transl Med 7: e10282, Jan 2022.
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL.: Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 39(27): 3044-3055, September 2021.
Qazilbash MH, Saini NY, Soung-Chul C, Wang Z, Stadtmauer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura SJ, Zhang T, Anderson AJ, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, Kwak LW.: A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood Sep 2021.
Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, Maxwell R, Arscott WT, Maity A, Jones JA, Plastaras JP, Stadtmauer EA, Levine BL, June CH, Milone MC, Paydar I.: The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clin Cancer Res Sep 2021.
Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus MV, Melenhorst JJ, Young RM, Jadlowsky JK, Marcucci KT, Bradner JE, Levine BL, Porter DL, Bushman FD, Kohli RM, June CH, Davis MM, Lacey SF, Vahedi G, Fraietta JA.: BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. J Clin Invest 131: e145459, Aug 2021.
Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, Cohen AD.: B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. British Journal of Haematology 193(4): 851-855, May 2021.
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL.: CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation 131(7): e144486, Apr 2021.